Key Takeaways VNDA won FDA approval for tradipitant, branded Nereus, to prevent vomiting caused by motion sickness.Vanda Pharmaceuticals said Nereus is the first new motion sickness drug in more than 40 years.VNDA shares surged 18% after hours following the approval, extending gains into pre-market trading.Vanda Pharmaceuticals, Inc. (VNDA) announced that the FDA has approved its candidate tradipitant for the prevention of vomiting induced by motion.The drug has been approved under the brand name Nereus.Tra ...

Lexaria Bioscience Corp. (NASDAQ:LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms relative to the Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (semaglutide) control study arm.“We are extremely pleased to not only have successfully achieved our primary endpoint,” stated Richard Christopher, CEO of Lexaria, “but to have also demonstrated obvious superiority in reducing unwanted side effects by as much ...